A 2026 scientific review has renewed interest in macroalgal compounds, including fucoidans, as possible ingredients for nutraceuticals and functional foods. Antioxidant and anti-inflammatory mechanisms are attracting attention, although promising laboratory biology does not mean clinical benefits are established.
The science behind the excitement
Brown and other seaweeds contain structurally diverse polysaccharides and additional bioactive compounds. Extraction method, molecular weight, sulfation pattern and raw-material species can influence the properties of a finished ingredient.
The challenge hidden behind the hype
Many reported mechanisms originate in laboratory or preclinical models. Clinical translation requires defined compositions, exposure information and controlled human studies. Seaweed products may also need rigorous testing for iodine content and contaminants such as heavy metals.
Where innovation could happen next
Green extraction technologies and analytical fingerprinting could improve sustainability and batch consistency. Manufacturers should prioritize identity testing, contaminant controls, stability and carefully substantiated health claims over generic antioxidant messaging.
Source and editorial note
Read the original reporting and research context. This independent editorial summary was prepared on 17 November 2026. It is not medical advice. Research findings do not establish that supplements prevent, treat or cure disease.








